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Abstract
Purpose To investigate the efects of Shared Decision-Making (SDM) using Routine Outcome Monitoring (ROM) primary 
on patients’ perception of Decisional Conlict (DC), which measures patients’ engagement in and satisfaction with clinical 
decisions, and secondary on working alliance and treatment outcomes.
Method Multi-centre two-arm matched-paired cluster randomised-controlled trial in Dutch specialist mental health care. 
SDM using ROM (SDMR) was compared with Decision-Making As Usual (DMAU). Outcomes were measured at baseline 
(T0) and 6 months (T1). Multilevel regression and intention-to-treat analyses were used. Post hoc analyses were performed 
on inluence of subgroups and application of SDMR on DC.
Results Seven teams were randomised to each arm. T0 was completed by 186 patients (51% intervention; 49% control) and 
T1 by 158 patients (51% intervention, 49% control). DC, working alliance, and treatment outcomes reported by patients did 
not difer signiicantly between two arms. Post hoc analyses revealed that SDMR led to less DC among depressed patients 
(p = 0.047, d =− 0.69). If SDMR was applied well, patients reported less DC (SDM: p = 0.000, d = − 0.45; ROM: p = 0.021, 
d = − 0.32), which was associated with better treatment outcomes.
Conclusion Except for patients with mood disorders, we found no diference between the arms for patient-reported DC. 
This might be explained by the less than optimal uptake of this generic intervention, which did not support patients directly. 
Regarding the positive inluence of a higher level of applying SDM and ROM on less DC and better treatment outcomes, the 
results are encouraging for further investments in patient-oriented development and implementation of SDMR.
Keywords Shared decision-making · Routine outcome monitoring · Outcome measurements · Decisional conlict · Cluster 
randomised-controlled trial
Introduction
Several studies have shown beneicial efects of Shared 
Decision-Making (SDM) in mental health care [1–5]. 
Patients report that they are better informed and more 
actively engaged in treatment, experience higher satisfac-
tion, and reduced decisional conlict, and patients show 
more treatment adherence. This can lead to better treat-
ment outcomes. SDM is the collaborative approach in 
which patients and clinicians share available information 
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from both perspectives and where patients are supported 
to participate actively in decision-making about treatment 
[6]. To participate in clinical decision-making, patients 
need access to information. Clinical feedback from out-
come measurements in everyday practice, so-called Rou-
tine Outcome Monitoring (ROM), could be helpful in deci-
sion-making about treatment [7–9]. ROM is a personalised 
source of information and implies regular measurements 
of clinical outcomes during treatment. It provides feedback 
on the patients’ progress [10, 11] and has the potential 
to be a useful tool to involve patients in their treatment 
process [7, 8, 12, 13]. Research has shown that ROM can 
enhance the communication between patients and clini-
cians, and, when patients and clinicians both are provided 
with this feedback information, ROM can have beneicial 
efects on mental health status, especially for patients who 
are not responding to treatment favourably [11, 13–16].
Hence, integrating systematic clinical feedback derived 
from ROM within a SDM framework could be consid-
ered a promising approach to improve the communication 
between patients and clinicians, encourage the empower-
ment of patients, and reduce decisional conlict (DC) [8]. 
DC refers to the degree to which patients were engaged 
in and felt comfortable about important clinical decisions 
[17–19]. In general, patients with less DC experience 
a better decision-making process. This leads to higher 
patient satisfaction with the clinician and can have posi-
tive efects on treatment engagement, well-being, and 
treatment outcome, whereas high DC has negative con-
sequences in terms of decisional delay, regret, treatment 
dropout, worse clinical outcomes, and a higher intention 
to complain about treatment [17, 19–22]. Therefore, in 
the National Quality Improvement Collaborative for the 
clinical use of ROM, we invested in the implementation 
and evaluation of SDM using ROM (SDMR) in Dutch spe-
cialist mental health care. Although scientiic knowledge 
about SDM [3, 5] and ROM [11, 13–16] as separate initia-
tives is expanding, no previous randomised-controlled trial 
(RCT) has investigated a combined SDMR approach in 
mental health care. As far as we know, only one pilot study 
[7] on the combination of SDM and ROM was conducted. 
This study showed the feasibility and utility of ROM as a 
personalised source of information while making shared 
decisions about treatment. To test the efects of this com-
bined approach, an RCT was recommended. Here, we 
present the results of a multi-centre two-arm cluster RCT 
aimed to investigate the efects of this approach on DC, 
the working alliance between patients and clinicians, and 
treatment outcomes. We compared SDMR with Decision-
Making As Usual (DMAU) and hypothesized that SDMR: 
(1) diminishes patients’ perception of decisional conlict, 
(2) improves the working alliance between patients and 
clinicians, and (3) leads to better treatment outcomes.
Methods
Study design and participants
This study was a multi-centre two-arm match-paired clus-
ter randomised-controlled trial (RCT) conducted in Dutch 
specialist mental healthcare in which the application of 
Shared Decision-Making using Routine Outcome Moni-
toring (SDMR) was compared with decision-making as 
usual (DMAU). 14 teams (7 intervention, 7 control) of 4 
specialist mental health care organisations were recruited 
to participate in this trial. The design of this study has 
been described in more detail elsewhere [8].
SDMR was intended to be suitable for a broad popula-
tion of patients treated in mental health care. Therefore, 
the trial involved teams treating patients with various 
diagnoses. The teams came from several catchment areas 
across the country (urban, semi-urban, and rural). To keep 
contamination to a minimum, we used a cluster design at 
the team level with pairs of two similar teams from the 
same mental health organisation being randomised.
Two complementary methods for recruiting patients 
were employed. First, clinicians of the intervention and 
control group consecutively invited each new patient to 
participate in the study. Second, in long-term treatment 
teams, patients were asked to participate at their annual 
treatment evaluation date. Patients were excluded from 
participating if they did not speak or read the Dutch lan-
guage or were incapable of completing questionnaires 
because of cognitive functioning or an ongoing crisis. 
Patients enrolled after receiving face to face and writ-
ten information about the study and after giving written 
informed consent.
Results are presented in accordance with the CON-
SORT statement for cluster randomised-controlled trials 
[23]. The trial was registered with The Netherlands Trial 
Registry (NTR5262).
Randomisation and blinding
After enrolment, random allocation of pairs of teams to 
either the experimental or control condition took place at 
cluster level by an independent statistician generating a 
random number (0 = DMAU, 1 = SDMR) by a SPSS syn-
tax. The pairs of teams of the same mental health organi-
sation treated a similar population of patients in the same 
geographical catchment area. Seven teams were allocated 
to the intervention group and seven teams to the control 
group. Due to the cluster randomisation and the nature of 
the intervention, blinding of the clinicians and patients 
was not possible. To reduce the risk of bias, data collection 
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was carried out by research assistants, independent of 
the research team and participating teams, with separate 
instruments, which were not part of the intervention.
Intervention
The RCT was part of a National Quality Improvement Col-
laborative (QIC), aimed to implement Routine Outcome 
Monitoring (ROM) in every day clinical practice [8, 9]. 
The intervention teams, which participated for a full year 
in the QIC program, implemented a model with ive steps 
to apply SDMR as a personalised source of information [8]. 
An essential part of this intervention was the implementa-
tion of ROM, tailored to the patient group, in routine clinical 
practice [9]. In addition, prior to the study, the clinicians 
of the intervention teams underwent a 1-day training in 
applying SDMR in clinical practice. Over the course of this 
study, the clinicians of all the intervention teams received 
one central booster session, and additionally intervention 
teams organised their own local, regular supervision ses-
sions. The researcher attended the supervision sessions of 
each team twice, aiming to monitor intervention integrity. A 
comprehensive description of the intervention can be found 
elsewhere [8, 9].
Data collection
Patients completed self-report questionnaires just after the 
start of SDMR (T0) and at 6-month follow-up (T1). Cli-
nicians answered questions regarding their patients at 6 
months (T1). Respondents received a link by email to com-
plete the questionnaires and if necessary received one or 
more reminders by email, mail, or phone. If patients did 
not use Internet, they received paper questionnaires by mail.
Outcomes
Primary outcome
Decisional conflict was measured in patients using the 
revised, validated decisional conflict scale (DCS) [17], 
which was translated into Dutch [8, 18]. Each of the 16 items 
is scored from 0 (strongly agree) to 4 (strongly disagree). 
Besides a total score, the DCS includes ive dimensions 
(information, support, clariication of values, certainty, and 
decision quality). Higher scores indicate more decisional 
conlict, which means that patients experience less infor-
mation, less support, less clariication, less certainty, and 
poorer decision quality about decision-making. To calculate 
the total scale and scores of the ive dimensions, the item 
scores were summed, divided by the number of items, and 
multiplied by 25. The scores thus range from 0 to 100 [17]. 
In general, the internal consistency of the total score and ive 
dimensions of the Dutch version of the DCS calculated in 
this study population is good [18].
To compare patients’ and clinicians’ views on Decisional 
Conlict, additionally, DC was measured on a Visual Ana-
logue (VAS) 10-point scale (item: ‘to what extent do you 
agree with the decision taken?’), illed out at T1 by both 
patients and clinicians (regarding their patients).
Secondary outcomes
We used the following validated self-report questionnaires 
to measure the secondary outcomes: Working Alliance 
Inventory Short Form (WAI-S) [24], Outcome Question-
naire (OQ-45) [25], and Manchester Short Quality of Life 
Measurement (MANSA-VN-16) [26]. At T1, the WAI-S was 
illed out by both patients and clinicians. Measurement of 
treatment outcomes was tailored to the patient group. There-
fore, the OQ-45, which measures symptom severity and 
functioning, was completed by patients in short-term treat-
ment, and the MANSA-VN-16, which gives insight in the 
patients’ perspective on the quality of life, by those in long-
term treatment. Cronbach’s alphas of these questionnaires 
calculated in this study population were: WAI-S α = 0.93; 
MANSA-VN-16 α = 0.89; OQ-45 α = 0.93.
Process outcomes
The process outcomes gave information about the inter-
vention integrity, which tests whether SDMR was prop-
erly applied in clinical practice. We tested this both in the 
experimental and in the control teams, because (elements 
of) SDMR have been adopted by many clinicians already. 
The SDM process was measured with the validated SDM-
Q-9 [27], and the application of ROM with four questions 
about the clinical use of ROM feedback [8]. At T1, both 
questionnaires were completed by patients and clinicians. 
The calculated Cronbach’s alphas in this study population 
were: SDM-Q-9 α ≥ 0.91 and ROM α ≥ 0.77.
Patients’ characteristics
At baseline, socio-demographics (gender, age, and educa-
tional level) and clinical characteristics (setting, primary 
diagnoses, and locus of control) [28] were collected.
Statistical analysis
Analyses were based on the intention-to-treat principle. 
Socio-demographical and clinical characteristics were calcu-
lated using descriptive statistics. We also tested for possible 
diferences in these characteristics between the two arms at 
T0 with independent samples t tests for the continuous and 
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Chi-square tests for the categorical variables [8]. To test for 
selective dropout before irst or follow-up measurement, dif-
ferences in baseline characteristics were assessed by logistic 
regression analyses. If participants had answered at least 
80% of the items on a questionnaire, missing items were 
imputed with the mean value of the completed items. To 
take into account cluster efects and to handle missing data 
[29], the analyses of the primary and secondary outcomes 
and process parameters were performed using linear multi-
level regression analysis (MLA) with three levels (teams, 
clinicians and patients). The analyses of the outcomes were 
based on the initial hypotheses performed with a two-tailed 
0.05 signiicance level. We were also interested in the efect 
sizes (Cohen’s d) of the diferences between the two arms, 
which were calculated by dividing the between-group difer-
ence by the pooled SD. The thresholds for interpreting the 
efect sizes were: small 0.00–0.32, medium 0.33–0.55, and 
large ≥ 0.56 [30]. Furthermore, the diferences in patients’ 
and clinicians’ views were tested. Finally, two post hoc anal-
yses were performed for the primary outcome DC. First, we 
assessed potential efect modiication by primary diagnoses 
and the degree of DC at T0. Interactions were tested for sig-
niicance at a p value of 0.1. Second, we performed, in line 
with the initial hypotheses, per-protocol analyses by inves-
tigating the inluence of intervention integrity on DC and 
the association between DC and treatment outcomes. MLA 
was performed in MLwiN 2.21 software. All other analyses 
were performed in SPSS 22.0.
Sample size
This study was powered to detect a medium-efect size of 
d = 0.5 on the primary outcome between intervention and 
control group. A sample size of 65 patients per arm was 
needed to obtain β = 0.80 power with alpha set at 0.05 
(two-tailed). To correct for clustering, we used an expected 
intra-cluster correlation coeicient (ICC) of 0.05 and cal-
culated [23, 31] that a sample size of 136 patients per arm 
was needed. Taking into account a dropout rate of 25%, we 
intended to include 182 patients per arm.
Results
Participant low
Inclusion took place between October 2015 and July 
2016. All measurements were completed in March 2017. 
14 teams (7 intervention and 7 control) of 4 organisa-
tions for specialist mental health care and 55 clinicians 
participated in the trial. As shown in Fig. 1, 227 patients 
gave informed consent and 186 patients (94 intervention, 
51%; 92 control, 49%) responded to the irst measure-
ment (T0). In a total 158 patients, 81 intervention (51%) 
and 77 control (49%) completed the follow-up measure-
ment at 6 months (T1). The range of participating patients 
per team was 4 to 28 (mean 13.3), and per clinician, the 
range was 1 to 11 patients (mean 3.38). The number of 
patients was in balance between the pairs of teams in 
the two arms. Clinicians completed an assessment at 6 
months for 173 patients: 90 (52%) from the intervention 
and 83 (48%) from the control group. The dropout rate of 
patients between inclusion and T0 was 18%, and between 
T0 and T1, it was 11%. Numbers of dropout were not sig-
niicantly diferent between the intervention and control 
group. In addition, the dropout rate was not signiicantly 
associated with any socio-demographic and most clinical 
characteristics. Only for locus of control was a signiicant 
diference found. Participants who dropped out between 
irst and follow-up measurement reported signiicantly 
higher locus of control (p = 0.034) compared to patients 
who completed the follow-up measurement. Reasons for 
dropout were: (1) withdrawal of informed consent (57%), 
(2) inability to complete questionnaires (23%), because of 
decreased cognitive capacity, current crisis, or death, and 
(3) patients not responding to reminders (20%).
Patients’ characteristics
Table 1 shows a complete overview of the socio-demo-
graphics (gender, age, and educational level) and clini-
cal characteristics (setting, primary diagnosis, and locus 
of control) of the study population, which were balanced 
between the two arms. Patients with the primary diag-
noses depressive (26%) and personality disorders (20%) 
were relatively the largest groups, followed by, respec-
tively, psychotic (17%), anxiety (15%), bipolar (13%), and 
other* (9%) disorders. Patients’ characteristics showed the 
variety of participating patients receiving diferent kinds 
of long-term and short-term treatment. All patients were 
treated in outpatient settings, but followed diferent types 
of treatment (for example: diferent kinds of individual 
or group psychotherapy, medication treatment, or sup-
port and guidance in daily life given by nurses). We could 
not extract information from electronic records at patient 
level about who exactly received which kinds of treatment. 
Because of these varieties in patients and treatment char-
acteristics, patients who participated in this trial also had 
to make decisions about various issues such as: diagnostic 
research, type of therapy, choices in medication treatment, 
personal treatment goals, or daytime activities.
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Efectiveness of the intervention
In the intention-to-treat analyses, no signiicant diferences 
between SDMR and DMAU on the primary outcome DC 
were found (Table 2), either for the total DC scale, or on 
the subdomains. We only found cluster efects within cli-
nicians (ICC 0.2) and did not ind evidence for clustering 
of the results at team level (ICC 0.0), which was also the 
unit of randomisation. Regarding the DC VAS scale, no 
signiicant diferences were found for the patient-reported 
version. Only, for the clinician, completed version was a 
diference found. Compared to the control group, clinicians 
in the intervention group reported on this VAS scale signii-
cantly more ‘agreement with the decision taken’ (β = 0.710, 
13 patients lost to follow up
9 withdrawal of informed consent
1 no response
3 not able to complete 
15 patients lost to follow up
8 withdrawal of informed 
consent
0 no response
7 not able to complete
Patients assessed for eligibility and
written informed consent, 227 patients
(intervention 121, control 106)
41 patients did not participate
(27 intervention, 14 control):
22 withdrawal of informed consent
13 no response (not answering to
reminders)
6 not able to complete questionnaires
7 teams
Patients: 94 baseline and 81 follow up.
Clinicians: 90 follow up. 
Intervention group: 7 teams.
94 patients allocated to intervention group
• Received allocated intervention (n= 94)
• Did not receive allocated intervention (n=
0)
T0 patient = 94
Control group: 7 teams.
92 patients allocated to control group
• Received allocated intervention (n=0)
• Did not receive allocated intervention 
(n= 92)
T0 patient = 92
7 teams
Patients: 92 baseline and 77 follow up
Clinicians: 83 follow up
T0
Analysis
14 teams, 186 patients randomized
Randomised at cluster level 
n = 14 teams: 2 x 7 teams of 4 organisations, matched pairs
7 teams, 
81 patients followed up in intervention group with 
T1
90 T1 clinicians (regarding their patients)
7 teams, 
77 patients followed up in control group with T1
83 T1 clinicians (regarding their patients)
Follow up (T1)
Enrollment
Fig. 1  Flow diagram RCT shared decision-making and ROM (Consort 2010)
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p = 0.018, 95%CI: 0.122–1.298) with a medium-efect size 
(d = 0.45). In addition, we found no signiicant efects of 
SDMR on patients’ reported secondary outcomes: working 
alliance, clinical outcome, and quality of life. According 
to clinicians, the working alliance was better in the inter-
vention group as compared to the control group (β = 0.254, 
p = 0.026 95%CI: 0.031–0,477; d = 0.45). Finally, although 
the application of SDM reported by patients and clinicians 
did not difer between conditions, both patients and clini-
cians experienced a signiicantly better usage of ROM in the 
intervention group compared to the control group (patients 
β = 10.980, p = 0.013, 95%CI: 2.289–19.671; clinicians: 
β = 25.558, p = 0.000, 95%CI: 17.930-33.186). The efect 
sizes were medium (patients: d = 0.39) to large (clinicians: 
d = 1.31).
When comparing patients’ with clinicians’ reported 
measurements, we found, irrespective of the condition, 
that clinicians, compared to patients, scored signiicantly 
higher (more positive) on the DC VAS scale  (meandif. 1.55, 
sd 2.96, p = 0.000, 95%CI: 1.069–2.028), WAI-S  (meandif. 
0.39, sd 0.98, p = 0.000, 95%CI: 0.240–0.539), SDMQ9 
 (meandif. 7.79, sd 32.46, p = 0.004, 95%CI: 2.531–13.040), 
and ROM questions  (meandif. 10.64, sd 35.19, p = 0.000, 
95%CI: 4.941–16.33).
Subgroup analyses
Post hoc analyses for the primary outcome DC (DCS total 
scale change T1−T0) showed significant interaction effects 
between primary diagnosis and trial condition, which means 
that the efect of SDMR on the primary outcome was signii-
cantly inluenced by the primary diagnosis as efect modiier. 
Table 3 demonstrates the intervention efects for each group 
of primary diagnoses. Patients with the primary diagnoses’ 
depression and anxiety demonstrated a reduced degree of 
DC in the intervention group at T1, whereas the other diag-
nosis groups showed an increased level of DC at follow-
up. For depressed patients, SDMR had a large efect (d = 
− 0.69) and was signiicantly more efective than DMAU 
(β = − 11.173, p = 0.047, 95%CI: − 22.176 to − 0.170). 
Furthermore, the level of experienced DC at T0 was also 
an efect modiier for the DCS total change score (Table 3). 
Table 1  Participants’ characteristics
*Other disorders: dissociative disorder NAO, dementia NAO, mood disorder by alcohol, undiferentiated somatoform disorder, hypochondria, 
and childhood disorder
No signiicant diferences were found between the two arms in socio-demographics and clinical characteristics’ (p < 0.05)
Total study population (n = 186) Intervention group (n = 94) Control group (n = 92)
Socio-demographics
Gender Female 111 (59.7%) 59 (62.8%) 52 (56.5%)
Male 75 (40.3%) 35 (37.2%) 40 (43.5%)
Age Mean age (sd) (min, max) 47.2 (18.0) (18–83 years) 47.2 (18.0) (18–80 years) 47.2 (18.2) (18–83 years)
Educational level Primary school or Lower second-
ary education (low)
68 (36.6%) 33 (35.1%) 35 (38.0%)
Higher secondary or intermediate 
vocational education (middle)
87 (46.8%) 45 (47.9%) 42 (45.7%)
Higher vocational education or 
university/Bachelor’s or Mas-
ter’s degree (high)
31 (16.7%) 16 (17.0%) 15 (16.3%)
Clinical characteristics
Setting Cure (short term) 100 (53.8%) 50 (53.2%) 50 (54.3%)
Severe mental illness (long term) 86 (46.2%) 44 (46.8%) 42 (45.7%)
Primary diagnosis Depressive disorder 48 (25.8%) 26 (27.6%) 22 (23.9%)
Personality disorder 38 (20.4%) 13 (13.8%) 25 (27.2%)
Psychotic disorder 32 (17.2%) 20 (21.3%) 12 (13.0%)
Anxiety disorder 27 (14.5%) 11 (11.7%) 16 (17.4%)
Bipolar disorder 24 (12.9%) 15 (16.0%) 9 (9.8%)
Other disorders* 17 (9.1%) 9 (9.6%) 8 (8.7%)
Locus of control Q1 Q1 11.0 Q1 10.0 Q1 11.0
Q2, median Q2 13.0 Q2 13.5 Q2 13.0
Q3 Q3 16.0 Q3 16.0 Q3 17.0
Minimum 5 5 5
Maximum 25 23 25
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Table 2  Diferences between intervention and control group on the primary and secondary outcomes and process parameters
C control group, I intervention Group, CI conidence interval
Primary outcome decisional conlict
T0 T1 β 95% CI p value Efect size
Mean (sd) T0, T1 Change score T1−T0
Total score C 39.79 (15·37) C 33.18 (16.52) 1.234 − 5.457 to 7.925 0.717 0.07
I 37.78 (18·99) I 33.03 (19.32)
Information C 44.51 (19·85) C 35.61 (19.99) 1.353 − 5.875 to 8.581 0.713 0.06
I 41.58 (22·56) I 33.64 (22.22)
Support C 36.36 (19·62) C 31.93 (17.70) 2.942 − 3.181 to 9.065 0.346 0.15
I 36.70 (20·68) I 34.05 (22.29)
Clariication C 39.26 (19.12) C 32.90 (19.49) − 0.788 − 9.771 to 8.195 0.862 − 0.03
I 38.12 (21.57) I 32.10 (21.61)
Certainty C 46.15 (20.84) C 37.88 (22.48) 3.962 − 3.533 to 11.457 0.300 0.16
I 41.58 (24.13) I 36.52 (24.24)
Quality C 35.00 (17.01) C 28.98 (18.08) 4.006 − 2.268 to 10.280 0.211 0.20
I 32.91 (19.98) I 29.92 (20.40)
Mean (sd) T1 T1
VAS DC patient C 7.40 (2.47) − 0.031 − 0.819 to 0.757 0.938 − 0.012
I 7.37 (2.60)
VAS DC clinician C 8.45 (1.79) 0.710 0.122 to 1.298 0.018 0.45
I 9.17 (1.32)
Secondary outcomes
Working alliance (WAV), clinical outcome (OQ-45), quality of life (MANSA-VN-16)
T0 T1 β 95% CI p value efect size
Mean (sd) T0, T1 Change score T1–T0
WAV patient C 3.53 (0.81) C 3.57 (0.89) − 0.020 − 0.257 to 0.217 0.869 − 0.03
Total score I 3.48 (0.88) I 3.54 (0.90)
Mean T1 T1
WAV clinician C 3.75 (0.53) 0.254 0.031 to 0.477 0.026 0.45
Total score I 4.00 (0.60)
OQ-45 C 78.06 (22.52) C 71.69 (24.73) − 0.964 − 9.702 to 7.774 0.828 − 0.05
Total score I 83.49 (27.52) I 78.07 (31.08)
MANSA-VN-16 C 4.25 (1.06) C 4.35 (0.94) − 0.234 − 0.491 to 0.022 0.074 − 0.42
Total score I 4.43 (0.99) I 4.30 (0.94)
Process parameters
SDM (SDMQ9) and ROM process
Mean T1 T1
SDMQ9 patient C 65.22 (23.94) − 0.834 − 8.405 to 6.737 0.828 − 0.03
I 64.39 (24.88)
SDMQ9 clinician C 69.61 (18.92) 5,544 − 1.349 to 12.437 0.115 0.31
I 75.78 (16.22)
ROM patient C 48.90 (28.30) 10.980 2.289 to 19.671 0.013 0.39
I 59.88 (27.78)
ROM clinician C 49.70 (22.56) 25.558 17.930 to 33.186 0.000 1.31
I 76.44 (16.01)
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Compared to the control group, patients in the intervention 
group with a lower level of DC at T0 reported more reduc-
tion in DC, while patients who experienced a high level of 
DC at T0 showed less reduction in DC at T1.
Associations between process and outcome 
parameters
As part of the post hoc analyses, we explored the associa-
tion between the process parameters SDMQ9 and ROM 
with the primary outcome DC (Table 4). We found that a 
better application of SDM and ROM, according to patients, 
led to signiicantly less DC (SDM β = − 0.217, p = 0.000, 
95%CI: − 0.321 to − 0.113; ROM β= − 0.111, p = 0.021, 
95%CI: -0.205 to − 0.017). The efect sizes were small 
(ROM d = − 0.32)-to-medium (SDM d = − 0.45). When 
clinicians reported a better SDM and ROM application, we 
did not ind signiicantly diferent DC scores in patients. 
Thus, in contrast to the clinicians’ reported level of SDM 
and ROM, when patients experienced a better application 
of SDM and ROM, this was associated with signiicantly 
decreased DC scores. Finally, we explored the inluence of 
DC on treatment outcomes (Table 4). We found signiicant 
associations (medium-efect sizes) between reduced DC 
and better clinical outcomes (β = 0.344, p = 0.001, 95% 
CI 0.134 to 0.554, d = 0.40,) and a higher quality of life 
(β = − 0.011, p = 0.006, 95% CI − 0.019 to − 0.0032, d 
= − 0.54).
Table 3  Results of subgroup analyses: diferences in change scores (T1–T0) on the primary outcome DC in the intervention group for diagnosis 
groups and level of DC at T0
Primary outcome decisional conlict (total score)
T0 T1 β 95% CI p value Efect size
Mean (sd) T0, T1 Change score T1 − T0
Depression C 36.01 (12.53) C 39.58 (16.10) − 11.173 − 22.176 to − 0.170 0.047 − 0.69
I 38.47 (16.55) I 31.96 (22.00)
Anxiety disorder C 38.57 (11.51) C 24.86 (11.28) − 4.003 − 18.297 to 10.291 0.583 − 0.30
I 46.31 (22.62) I 33.52 (15.83)
Psychotic disorder C 38.80 (15.13) C 28.75 (9.29) 13.206 − 1.545 to 27.957 0.079 0.97
I 29.12 (16.87) I 27.54 (16.08)
Personality disorder C 44.06 (15.84) C 35.81 (20.23) 3.478 − 8.750 to 15.706 0.577 0.14
I 47.60 (18.17) I 44.89 (22.73)
Bipolar disorder C 33.98 (16.15) C 23.18 (15.16) 11.055 − 5.433 to 27.543 0.189 0.65
I 39.58 (19.25) I 35.55 (14.90)
Rest category C 46.09 (24.32) C 35.35 (13.15) 6.575 − 10.136 to 23.286 0.440 0.59
I 27.43 (17.44) I 26.37 (19.77)
Low level of DC at T0 C 26.83 (6.27) C 27.71 (15.13) − 1.777 − 9.807 to 6.253 0.665 − 0.12
I 24.43 (9.83) I 24.20 (13.99)
High level of DC at T0 C 50.64 (11.89) C 37.50 (16.45) 1.203 − 6.813 to 9.219 0.768 0.06
I 55.03 (13.10) I 44.64 (19.36)
Table 4  Associations of 
process parameters with the 
primary outcome DC and the 
inluence of DC change score 
on treatment outcomes
β 95% CI p value Efect size
Associations between process parameters and primary outcome
Decisional conlict
Total score change T1–T0
SDMQ9 patient T1 − 0.217 − 0.321 to − 0.113 0.000 − 0.45
SDMQ9 clinician T1 0.014 − 0.164 to 0.192 0.878 0.23
ROM patient T1 − 0.111 − 0.205 to − 0.017 0.021 − 0.32
ROM clinician T1 − 0.044 − 0.179 to 0.091 0.523 0.00
Associations between primary outcome and treatment outcomes
OQ-45
Total score change T1–T0
Decisional conlict
Total score change T1 − T0
0.344 0.134 to 0.554 0.001 0.40
MANSA-VN-16
Total score change T1–T0
Decisional conlict
Total score change T1–T0
− 0.011 − 0.019 to − 0.0032 0.006 − 0.54
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Discussion
This study presents the results of a cluster randomised-
controlled trial, testing the application of Shared Decision-
Making using Routine Outcome Monitoring (SDMR) in 
specialist mental health care. Compared to decision-mak-
ing as usual (DMAU), we found no signiicant inluence 
of SDMR on the primary outcome reduction of Decisional 
Conlict (DC) reported by patients. Furthermore, there 
were no signiicant diferences in the patients’ rated sec-
ondary outcomes (working alliance, clinical outcome, and 
quality of life) between the two arms. In contrast to the 
patients’ rated outcome parameters, the clinicians in the 
intervention group reported a signiicantly better working 
alliance and experienced more agreement with the clinical 
decisions that were taken. Subgroup analyses showed that 
that efect of the intervention was signiicantly modiied 
by diagnosis. Depressed patients reported a signiicant 
and large efect of SDMR on reduction of DC. Looking at 
important process parameters, both patients and clinicians 
in the intervention group reported a signiicantly better 
application of ROM. Patients reported medium efects, 
while clinicians reported very large efects. The SDM pro-
cess rated by clinicians and patients did not difer between 
the groups. In general, irrespective of the condition, clini-
cians’ views about the outcome and process parameters 
were significantly more positive than patients’ rated 
parameters. Exploring the inluence of the process param-
eters on DC demonstrated that a better implementation of 
SDMR was associated with signiicantly less DC expe-
rienced by patients. Thus, when, according to patients, 
SDMR was applied well, patients reported a reduction of 
DC, which had a positive inluence on clinical outcomes 
and quality of life.
Interpretation and clinical implications
To our knowledge, this is the irst RCT to rigorously test 
the efectiveness of a combined SDM with ROM initia-
tive in mental health care. In contrast with our hypotheses 
and previous research [1–5, 11, 13–16], we found no sig-
niicant diferences between SDMR and DMAU regarding 
the primary and secondary outcomes reported by patients. 
Interestingly, the results of the clinicians on DC and work-
ing alliance in the intervention group were signiicantly 
more positive compared to the control group. A possible 
explanation for the lack of diferences between the con-
ditions on the patients’ rated outcome parameters is that 
SDMR was not optimally implemented. First, this could 
be evidenced by the fact that, although clinicians in the 
intervention group reported change, patients did not notice 
much diference. A second argument is that, despite the 
investment in training, booster, and supervision sessions, 
the application of SDM, reported by patients and clini-
cians, did not difer between the two arms. Only the usage 
of ROM was signiicantly better in the intervention group 
according to both patients and clinicians. When looking 
at the association between the process parameters and the 
primary outcome, we found, in line with our hypotheses 
and previous research [1–5, 11, 13–16], that a better appli-
cation of SDMR led to less DC. Thus, if clinicians were 
able to adequately apply SDMR during treatment consulta-
tions with their patients, this approach resulted in positive 
efects for patients. Less DC was, in turn, associated with 
better clinical outcomes and better quality of life.
Moreover, the subgroup analyses indicated that the efect 
of the intervention difered between subgroups of patients, 
with a signiicantly positive efect for depressed patients. 
This is in line with previous research which revealed that 
shared decision-making had a positive impact on depressed 
patients in terms of satisfaction and treatment adherence 
[3]. Previous work also demonstrated that feedback during 
treatment led to better outcomes in patients with mood dis-
orders [16, 32]. This may imply that the intervention was 
too generic for the variety of patients treated in specialist 
mental health care. In designing the study, we hoped to be 
able to arrive at a generic method to improve SDM across 
mental health, and we approached teams treating very difer-
ent types of patients. However, tailoring the intervention to 
the patient group and its decision topics may be necessary to 
improve results. Previous work has shown that the success of 
SDM depends on the patients’ ability to participate actively 
[33, 34]. A limitation of our intervention is that we focused 
our training on clinicians. Future interventions should target-
ing both patients and clinicians [33, 34].
Strengths and limitations
Our study had various strengths. First, due to the matched 
pair randomisation between similar teams, the risk of con-
founding was reduced. This was evidenced by the fact that 
no diferences were found in patients’ characteristics and 
dropout rates between the two arms. Second, because this 
study was conducted in real-world clinical practice with a 
heterogeneous patient population, including various ages, 
diagnostic groups, and treatment settings, the study results 
were generalizable to a large group of mental health care 
teams, and thus had good external validity. Because of this 
heterogeneity, we were also able to investigate diferences in 
efects for subgroups of patients. Third, the independent data 
collection with separate research instruments apart from the 
intervention prevented socially desirable scoring of patients 
and undesired inluence of the research team or clinicians on 
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the results. In addition, it enhanced the uniformity and qual-
ity of the collected data. Furthermore, at T1, we had insight 
into both patients’ and clinicians’ views on the application 
of SDMR. Finally, we used multilevel analyses to correct for 
the variability of the results at clinician level.
This study also had a number of limitations. Despite the 
extra eforts (recruiting an additional pair of two teams, 
checking if all eligible patients were asked to participate in 
the study and extending the inclusion period by a maximum 
of 5 months), the study population of 186 patients with a 
irst measurement was smaller than intended. Reasons for 
this smaller population were di culties in recruiting patients 
due to the lower inlow of patients receiving treatment from 
the participating teams and fewer patients who were willing 
to participate in the study. Because of the end date of the 
national collaborative and its funding, we could not extend 
the inclusion period further. Although the estimated sample 
size was not reached, the study population of 186 patients, 
with more than 90 patients per arm and the balance between 
arms in patients’ characteristics and dropout rates, proved 
suicient to detect medium-efect sizes. Looking at the efect 
sizes of the primary analyses, these were extremely small, 
suggesting that power was not a deciding factor in our nega-
tive results of the primary outcome. Furthermore, although 
we adopted a cluster randomised-controlled design to reduce 
the risk of contaminating the two conditions, contamina-
tion cannot be ruled out altogether and may have weak-
ened the efects found. Finally, treatment outcomes were 
evaluated, tailored to the patient groups, with two diferent 
measurement instruments. Patients who received short-term 
treatment illed out the OQ-45, which measures symptom 
severity and functioning. Patients who followed long-term 
treatment completed the MANSA-VN-16 which measured 
quality of life. Therefore, we have partially insight into the 
efects of SDMR on symptom severity, merely for patients 
who followed short-term treatment.
Conclusions
To our knowledge, this is the irst randomised-controlled 
trial (RCT) which investigated the combination of Shared 
Decision-Making using Routine Outcome Monitoring 
(SDMR) in specialist mental health care.
In general, this study showed no efects of SDMR on pri-
mary and secondary outcomes rated by patients. However, 
subgroup analyses revealed a positive efect of SDMR on 
DC for depressed patients. According to clinicians, SDMR 
has a positive impact on DC and the working alliance. Fur-
thermore, in the intervention group, both patients and clini-
cians reported a better ROM application. Finally, taking par-
ticipants of both arms into account, a higher level of SDMR 
led to less DC, which, in turn, had a positive inluence on 
treatment outcomes. Although this is a negative trial, the 
results are encouraging for further investments in the devel-
opment, implementation, and investigation of this approach 
in clinical practice.
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